GLMD

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for liver, metabolic, and inflammatory diseases. The company's lead product candidate targets non-alcoholic steatohepatitis (NASH) and other chronic liver conditions affecting millions of patients worldwide. Galmed conducts clinical trials to evaluate the safety and efficacy of its drug candidates, seeking regulatory approval for commercialization. As a development-stage company, Galmed does not yet generate product revenue and relies on financing activities to fund its research and clinical programs.